Latest Breaking News On - Surufatinib development - Page 1 : comparemela.com

HUTCHMED Receives Complete Response Letter from the U S FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic (“pNETs”) and .

United statesHong kongNew jerseyFlorham parkMarek kaniaWeiguo suCompany nasdaqDrug administrationSurufatinib developmentChina limitedJapanese pharmaceuticalsDevices agencyComplete response letterNew drug applicationTrack designationsOrphan drug designation

HUTCHMED Receives Complete Response Letter from the U S FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesHong kongNew jerseyFlorham parkMark leeZhou yiAtholl tweedie freddy crossleyMarek kaniaBen atwell alex shawWeiguo suAnnie chengStock exchange of hong kongCompany nasdaqDrug administrationSurufatinib developmentExchange commission

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple disease settings, presented at the Europ.

Ying chengUnited statesHong kongMing luZhou yiAtholl tweedie freddy crossleyBen atwell alex shawMark leeJunshi biosciencesAnnie chengStock exchange of hong kongUniversity cancer hospital instituteDrug administrationSurufatinib developmentExchange commissionChina limited

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomStudy groupDrug administrationSurufatinib developmentChina limitedJapanese pharmaceuticalsEuropean unionEuropean medicines agencyNational medical products administration of chinaDevices agencyKnowledge networkFlorham parkMedical devices agencyMarketing authorization applicationNational medical products administration

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomMark leeZhou yiAtholl tweedie freddy crossleyBen atwell alex shawAnnie chengStock exchange of hong kongStudy groupDrug administrationSurufatinib developmentExchange commissionChina limitedJapanese pharmaceuticalsEuropean unionEuropean medicines agency